Xarelto Back On Track: J&J Answers "Complete Response" Letter And Files For Atrial Fibrillation
This article was originally published in The Pink Sheet Daily
Executive Summary
Simultaneously, partner Bayer submits applications in Europe, where rivaroxaban already is approved, for those indications and one more.
You may also be interested in...
FDA Approval Of Xarelto Bodes Well For Drug’s Future Expansion
The July 1 approval of Johnson & Johnson’s novel anticoagulant Xarelto for prevention of deep vein thrombosis is an important step for J&J and its ex-U.S. partner Bayer AG as they gear up to play in the highly promising but increasingly complicated world of novel anticoagulants.
FDA Approval Of Xarelto Bodes Well For Drug’s Future Expansion
The July 1 approval of Johnson & Johnson’s novel anticoagulant Xarelto for prevention of deep vein thrombosis is an important step for J&J and its ex-U.S. partner Bayer AG as they gear up to play in the highly promising but increasingly complicated world of novel anticoagulants.
Xarelto Approval For DVT Bodes Well For Coming Indications
FDA's July 1 approval of Johnson & Johnson's oral anticoagulant comes after a long review process, and in front of some key decision points that will shape the rivaroxaban program's future.